Literature DB >> 14749500

Phosphorylation of RNA polymerase II in cardiac hypertrophy: cell enlargement signals converge on cyclin T/Cdk9.

Prathit A Kulkarni1, Motoaki Sano, Michael D Schneider.   

Abstract

Cardiac myocyte enlargement is the eponymous characteristic of cardiac hypertrophy, regardless of the instigating signal. Such triggers include biomechanical stress (e.g., work load, compensation for ischemic damage), sarcomeric protein mutations, cytoskeletal protein mutations, abnormal energetics, G protein-coupled receptors for ligands (including angiotensin II and endothelin-1), or their signal transducers within cells. In turn, increased myocyte size reflects increased RNA and protein content per cell as responses to these stimuli. In eukaryotic cells, the large subunit of RNA polymerase II (RNAPII) becomes extensively phosphorylated in its serine-rich C-terminal domain (CTD) during the transition from transcript initiation to transcript elongation - that is, "escape" of RNAPII from the promoter-proximal region into the open reading frame. Although this process is believed to be crucial to productive synthesis of mRNA and is known to be governed by two atypical cyclin-dependent kinases, Cdk7 and Cdk9, surprisingly little is understood of how regulatory pathways within cells intersect these RNAPII-directed protein kinases. Investigations of the CTD kinase module in cardiac hypertrophy provide a tentative initial map of a molecular circuit controlling cell size through regulated phosphorylation of RNAPII.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14749500     DOI: 10.1210/rp.59.1.125

Source DB:  PubMed          Journal:  Recent Prog Horm Res        ISSN: 0079-9963


  11 in total

Review 1.  How do mutations in contractile proteins cause the primary familial cardiomyopathies?

Authors:  Steven B Marston
Journal:  J Cardiovasc Transl Res       Date:  2011-03-22       Impact factor: 4.132

Review 2.  Ready, pause, go: regulation of RNA polymerase II pausing and release by cellular signaling pathways.

Authors:  Xiuli Liu; W Lee Kraus; Xiaoying Bai
Journal:  Trends Biochem Sci       Date:  2015-08-04       Impact factor: 13.807

3.  Cyclin K goes with Cdk12 and Cdk13.

Authors:  Jiri Kohoutek; Dalibor Blazek
Journal:  Cell Div       Date:  2012-04-18       Impact factor: 5.130

4.  Oligomerization of HEXIM1 via 7SK snRNA and coiled-coil region directs the inhibition of P-TEFb.

Authors:  Dalibor Blazek; Matjaz Barboric; Jiri Kohoutek; Irena Oven; B Matija Peterlin
Journal:  Nucleic Acids Res       Date:  2005-12-23       Impact factor: 16.971

5.  Dnmt2/Trdmt1 as Mediator of RNA Polymerase II Transcriptional Activity in Cardiac Growth.

Authors:  Hossein Ghanbarian; Nicole Wagner; Beatrice Polo; Delphine Baudouy; Jafar Kiani; Jean-François Michiels; François Cuzin; Minoo Rassoulzadegan; Kay-Dietrich Wagner
Journal:  PLoS One       Date:  2016-06-06       Impact factor: 3.240

6.  P-TEFb- the final frontier.

Authors:  Jiri Kohoutek
Journal:  Cell Div       Date:  2009-09-02       Impact factor: 5.130

7.  The RNA degradation pathway regulates the function of GAS5 a non-coding RNA in mammalian cells.

Authors:  Hidenori Tani; Masaki Torimura; Nobuyoshi Akimitsu
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

8.  HEXIM1 is a promiscuous double-stranded RNA-binding protein and interacts with RNAs in addition to 7SK in cultured cells.

Authors:  Qintong Li; Jeffrey J Cooper; Gary H Altwerger; Michael D Feldkamp; Madeline A Shea; David H Price
Journal:  Nucleic Acids Res       Date:  2007-03-29       Impact factor: 16.971

9.  Cellular mRNA activates transcription elongation by displacing 7SK RNA.

Authors:  Tara M Young; Michael Tsai; Bin Tian; Michael B Mathews; Tsafi Pe'ery
Journal:  PLoS One       Date:  2007-10-10       Impact factor: 3.240

Review 10.  Role of noncoding RNAs in the regulation of P-TEFb availability and enzymatic activity.

Authors:  Giuliana Napolitano; Luigi Lania; Barbara Majello
Journal:  Biomed Res Int       Date:  2014-02-19       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.